New Hair Loss Treatments: Is Hair Restoration Entering a New Era?
For decades the main medical treatments for male pattern hair loss have remained broadly unchanged. For men, finasteride and minoxidil are still the most established options. Both can be effective, but neither works for everyone. Minoxidil requires continued use, while finasteride can cause unwanted side effects in a minority of patients.
That has created a clear need for better options. At the moment several new hair loss treatments are moving through clinical trials. Some target the androgen pathway while other ones aim to reactivate dormant follicles or influence hair growth through completely different mechanisms.
The investment world has started to notice too. Recent coverage has compared the level of interest in emerging hair-loss drugs with the earlier excitement surrounding GLP-1 medicines for obesity. That comparison needs some caution. No new hair loss treatment has yet shown the impact GLP-1 medicines have produced in weight management.
Dr Peter Thomas
MBBS MRCGP FUE Hair Transplant Surgeon
UK-trained doctor and specialist FUE hair transplant surgeon with postgraduate qualifications including MRCGP and specialist training to CCT level. Bringing refined FUE hair restoration techniques and renowned for natural results.
Why Current Hair Loss Treatments Still Have Limitations
Minoxidil
Topical minoxidil can improve density and prolong the growth phase but results vary. Daily application can be inconvenient and may irritate the scalp. Low dose oral minoxidil is also suggested by specialists but it remains off-label for hair loss and can cause systemic effects such as excess body hair, fluid retention or changes in blood pressure.
Finasteride
Finasteride lowers dihydrotestosterone (DHT) which is one of the main drivers of male pattern hair loss. It can significantly slow progression in suitable patients. However, some men are reluctant to take a longterm hormonal treatment because of concerns around sexual or psychological side effects.
These limitations are one reason researchers are exploring new treatments for male pattern baldness that work more locally or through entirely different pathways.
PP405 for Hair Loss: Could Dormant Follicles Be Reactivated?
One of the most discussed emerging treatments is PP405. Unlike finasteride, PP405 does not primarily target DHT. It is an inhibitor of the mitochondrial pyruvate carrier. Researchers hope this changes metabolism within hair follicle stem cells. The aim is to encourage dormant follicles to return to an active growth phase.
The Phase 2a study had 78 adults with androgenetic alopecia (ClinicalTrials.gov, 2025). Early results attracted considerable interest. According to Pelage Pharmaceuticals, 31% of selected treated men achieved more than a 20% increase in hair density. This occurred after eight weeks. No participants in the corresponding placebo group achieved that threshold. The company also reported that the study met its primary safety endpoint. No systemic PP405 was detected in blood (Pelage Pharmaceuticals, 2025).
These findings sound impressive but they need context. This was a relatively small and early trial rather than a large Phase III study. Therefore, PP405 for hair loss remains promising but experimental. Larger studies must confirm its effectiveness and determine whether improvements persist.
Clascoterone for Hair Loss: A New Alternative to Finasteride?
Clascoterone 5%, also known as Breezula during development, is considerably further along. It works by blocking androgen receptors locally within the scalp. That creates an important difference from finasteride. Finasteride reduces DHT production systemically. Clascoterone instead aims to reduce androgen activity directly around the hair follicle.
Two pivotal Phase III studies had 1,465 men with androgenetic alopecia. Both studies found that clascoterone increased hair counts more than the inactive treatment. In one study, the improvement was about 5.4 times greater than the control group. In the second, it was about 1.7 times greater (Cosmo Pharmaceuticals, 2025).
These figures can sound dramatic, so they need context. They do not mean patients grew 539% more hair. Instead, they compare how much better clascoterone performed than the inactive treatment used in the study.
Clascoterone has already completed major Phase III studies. It is therefore among the new hair loss drugs closest to possible regulatory approval. Availability in some markets during 2027–2028 appears plausible if regulatory review progresses smoothly. UK approval could follow a different timetable.
VDPHL01: A New Version of Oral Minoxidil
VDPHL01 is another advanced treatment although it uses a familiar drug (minoxidil). It is an extended-release oral minoxidil formulation developed specifically for pattern hair loss.
A Phase 2/3 study tested VDPHL01 in 519 men with pattern hair loss. After six months men taking the treatment gained around 30–33 additional thicker hairs per cm² in the measured scalp area. The placebo group gained around 7 hairs per cm². Both once a day and twice a day treatments performed significantly better than placebo (Veradermics, 2026).
VDPHL01 therefore does not introduce an entirely new biological mechanism. Instead, it could standardise a treatment already familiar to many hair loss specialists. A confirmatory Phase III study is underway.
GT20029: Targeting the Androgen Receptor Itself
GT20029 works in a different way from finasteride. Instead of lowering DHT levels, it aims to reduce the number of androgen receptors that DHT can act on. It is applied directly to the scalp. The treatment is designed to help the body break down these receptors within the treated area.
A Phase II study included 180 men with male pattern hair loss. After 12 weeks, men receiving GT20029 showed increases in thicker, visible hairs compared with the start of the study. Some treatment schedules also performed significantly better than placebo. Side effects were generally similar between the treatment and placebo groups, and most were mild (Hu et al., 2025).
GT20029 is still experimental and needs further study. However, it shows how future treatments may target hair loss in new ways beyond simply reducing DHT.
Could Hair Loss Have a “GLP-1 Moment”?
The GLP-1 comparison is useful because obesity had a high unmet need and relatively limited drug options. New biological treatments like Mounjaro and Wegovy then transformed the field.
Hair loss may now be entering a similar period of rapid innovation. Researchers are now investigating several different biological pathways simultaneously. That raises the possibility that future hair loss treatments could become more personalised and effective. However, none has yet demonstrated anything comparable with the clinical impact of GLP-1 medicines.
Hair Transplant or Medication?
Medication and hair transplantation solve different problems.
Medicines work best when follicles remain present but are becoming weaker, thinner or less active. A hair transplant moves donor follicles into areas where useful hair has already been lost. Therefore, new medicines are unlikely to make hair transplantation obsolete. This also explains why hair loss treatment before a hair transplant can sometimes be important. Stabilising ongoing loss can improve surgical planning. It may also help preserve valuable donor hair for the future.
Will New Drugs Change the Best Hair Loss Treatment for Men?
Current treatment usually centres around finasteride, minoxidil, non-surgical interventions (PRP and LLLT) and hair transplantation where appropriate.
In future, the best hair loss treatment for men may combine several approaches. The exact combination could depend on the stage and biology of hair loss. Someone with early miniaturisation may mainly benefit from medication. Someone with established frontal baldness may still require transplantation. Treatment should therefore remain individual rather than being based around one medicine or procedure.
Where useful follicles have already been lost, FUE hair transplantation can redistribute donor hair into areas that medication cannot reliably restore.
What Should Hair Loss Patients Do Now?
Patients should not stop proven treatment simply because a new drug appears in the news. Encouraging early trial results do not always produce successful licensed medicines. For someone experiencing hair loss it’s important to get an assessment to help:
- Establish the likely diagnosis
- Assess whether hair loss remains progressive
- Discuss treatment options
- Plan hair transplantation
If you are unsure whether medication, surgery or further investigation is appropriate, arranging a consultation with Dr Thomas and the team allows your hair loss and donor area to be assessed individually.
Patients should also avoid buying unofficial versions of these experimental medicines online.
If you are considering surgery, understanding hair transplant recovery and growth can help set realistic expectations about when changes become visible.
A final word from Dr Thomas...
Hair loss treatment is entering a genuinely exciting period. New drugs may eventually give patients more effective and more personalised options. However, promising trial results are not the same as proven treatments. For now, patients should rely on established therapies and careful clinical assessment.
The future will probably not be one breakthrough drug. It is more likely to combine medication, newer regenerative treatments and hair transplantation in a more individual way.
Speak with Dr Thomas and the team by booking a consultation today. You can also find more information about hair transplants on Dr Thomas’s Instagram.
References
Absci Corporation (2026) Absci announces positive interim Phase 1 data from the HEADLINE™ trial of ABS-201, a novel antibody targeting the prolactin receptor. 24 June 2026.
ClinicalTrials.gov (2025) Safety, pharmacokinetics and efficacy of PP405 in adults with androgenetic alopecia. NCT06393452. Bethesda, MD: U.S. National Library of Medicine.
Cosmo Pharmaceuticals N.V. (2025) Phase III topline results from SCALP 1 and SCALP 2 for clascoterone 5% solution in male androgenetic alopecia. 3 December 2025.
Hu, R., Wei, A., Wu, L., Yang, B., Li, J., Li, L., Zhao, Y., Yang, C., Zhang, G., Li, Y., Wan, J., Wang, H., Wang, M., Ni, X., Tong, Y. and Yang, Q. (2025) ‘Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study’, Journal of Dermatological Treatment, 36(1), 2574304. doi:10.1080/09546634.2025.2574304.
Pelage Pharmaceuticals (2025) Pelage Pharmaceuticals announces $120 million Series B financing to advance regenerative medicine treatments for hair loss. Includes interim Phase 2a PP405 clinical findings.
Veradermics, Inc. (2026) Oral VDPHL01 achieved early, consistent and robust hair growth in positive Phase 2/3 Study 302 in male pattern hair loss. 27 April 2026.
Veradermics, Inc. (2026) VDPHL01 clinical development pipeline. Phase III registration programme for pattern hair loss.
